Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy.
10.3779/j.issn.1009-3419.2021.101.26
- Author:
Xiaoyu GUO
1
;
Ti WEN
1
;
Xiujuan QU
1
Author Information
1. Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
- Publication Type:Journal Article
- Keywords:
Adverse events;
Combination therapy;
PD-1/PD-L1 inhibitors;
Tumor
- From:
Chinese Journal of Lung Cancer
2021;24(7):513-518
- CountryChina
- Language:Chinese
-
Abstract:
The development of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of cancer patients, but a large population of patients are still ineffective to ICIs treatment or develop aquired drug resistance. In order to improve the clinical benefits, a number of studies on ICIs based combination therapy have been actively explored, and have achieved satisfactory results. With the application of ICIs based combination therapy in clinical practice, increasing attention has been paid to the safety of combination therapy and the management of treatment-related adverse events. In this review, the characteristics of adverse events related to ICIs based combination therapies, especially programmed cell death protein 1/protein ligand 1 (PD-1/PD-L1) inhibitors are discussed, in order to provide profound thoughts for toxicity evaluation and individualized treatment decision in future clinical practice.
.
